Matthias Muhar

Matthias Muhar

Auto-generated profile, based on publicly available information

Matthias Muhar

Institute of Molecular Health Sciences, Department of Biology, Swiss Federal Institute of Technology (ETH) Zurich, Zurich, Switzerland

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2017 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
GWGordana Wutz
Gordana Wutz
CVCsilla Várnai
Csilla Várnai
KNKota Nagasaka
Kota Nagasaka
DCDavid A Cisneros
David A Cisneros
RSRoman R Stocsits
Roman R Stocsits
JPJan‐Michael Peters
Jan‐Michael Peters
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

1 December 2013 in Cell Reports
Verified
Journal Article
Open access
CFChristof Fellmann
Christof Fellmann
THThomas Hoffmann
Thomas Hoffmann
VSVaishali Sridhar
Vaishali Sridhar
BHBarbara Hopfgartner
Barbara Hopfgartner
MMMatthias Muhar
Matthias Muhar
JZJohannes Zuber
Johannes Zuber
Short hairpin RNA (shRNA) technology enables stable and regulated gene repression. For establishing experimentally versatile RNAi tools and minimizing toxicities, synthetic shRNAs can be embedded into endogenous microRNA contexts. However, due to our incomplete understanding of microRNA biogenesis, such "shRNAmirs" often fail to trigger potent knockdown, especially when expressed from a single genomic copy. Following recent advances in design of synthetic shRNAmir stems, here we take a systematic approach to optimize the experimental miR-30 backbone. Among several favorable features, we identify a conserved element 3' of the basal stem as critically required for optimal shRNAmir processing and implement it in an optimized backbone termed "miR-E", which strongly increases mature shRNA levels and knockdown efficacy. Existing miR-30 reagents can be easily converted to miR-E, and its combination with up-to-date design rules establishes a validated and accessible platform for generating effective single-copy shRNA libraries that will facilitate the functional annotation of the genome.

14 September 2015 in Nature
Verified
Journal Article
Closed access
PDF file
Philipp RathertPhilipp Rathert
Philipp Rathert
MRMareike Roth
Mareike Roth
TNTobias Neumann
Tobias Neumann
FMFelix Muerdter
Felix Muerdter
JRJae-Seok Roe
Jae-Seok Roe
JZJohannes Zuber
Johannes Zuber

27 November 2013 in Genes & Development
Verified
Journal Article
Open access
PDF file
JSJunwei Shi
Junwei Shi
WWWarren A. Whyte
Warren A. Whyte
CZCinthya J. Zepeda-Mendoza
Cinthya J. Zepeda-Mendoza
JMJoseph P. Milazzo
Joseph P. Milazzo
CSChen Shen
Chen Shen
CVChristopher R. Vakoc
Christopher R. Vakoc
Cancer cells frequently depend on chromatin regulatory activities to maintain a malignant phenotype. Here, we show that leukemia cells require the mammalian SWI/SNF chromatin remodeling complex for their survival and aberrant self-renewal potential. While Brg1, an ATPase subunit of SWI/SNF, is known to suppress tumor formation in several cell types, we found that leukemia cells instead rely on Brg1 to support their oncogenic transcriptional program, which includes Myc as one of its key targets. To account for this context-specific function, we identify a cluster of lineage-specific enhancers located 1.7 Mb downstream from Myc that are occupied by SWI/SNF as well as the BET protein Brd4. Brg1 is required at these distal elements to maintain transcription factor occupancy and for long-range chromatin looping interactions with the Myc promoter. Notably, these distal Myc enhancers coincide with a region that is focally amplified in ∼3% of acute myeloid leukemias. Together, these findings define a leukemia maintenance function for SWI/SNF that is linked to enhancer-mediated gene regulation, providing general insights into how cancer cells exploit transcriptional coactivators to maintain oncogenic gene expression programs.

18 May 2018 in Science
Verified
Journal Article
Closed access
PDF file
MMMatthias Muhar
Matthias Muhar
AEAnja Ebert
Anja Ebert
TNTobias Neumann
Tobias Neumann
CUChristian Umkehrer
Christian Umkehrer
JJJulian Jude
Julian Jude
JZJohannes Zuber
Johannes Zuber
Profiling transcription—a SLAM dunk: Identification of the direct target genes of transcription factors could shed light on how healthy cells become malignant. Muhar et al. applied a modified version of a transcript-mapping method called SLAM-seq to identify the target genes of two transcriptional regulators of major interest in cancer research (see the Perspective by Sabò and Amati). The MYC oncoprotein selectively activates transcription of just a few genes, primarily those involved in basic cell metabolism. In contrast, BRD4, a bromodomain-containing protein that is being targeted for cancer therapy, activates transcription of many genes. Science , this issue p. 800 ; see also p. 713

31 October 2016 in Nature Reviews Genetics
Verified
Journal Article
Closed access
PDF file
BHBenjamin Housden
Benjamin Housden
MMMatthias Muhar
Matthias Muhar
MGMatthew Gemberling
Matthew Gemberling
CGCharles A. Gersbach
Charles A. Gersbach
DSDidier Y. R. Stainier
Didier Y. R. Stainier
NPNorbert Perrimon
Norbert Perrimon